Canada markets open in 3 hours 27 minutes

IMV Inc. (IMV.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
1.8000+0.0200 (+1.12%)
At close: 04:00PM EST

IMV Inc.

130 Eileen Stubbs Avenue
Suite 19
Dartmouth, NS B3B 2C4
Canada
902 492 1819
https://www.imv-inc.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees77

Key Executives

NameTitlePayExercisedYear Born
Mr. Andrew Hall M.Sc.Interim CEO & Chief Bus. Officer356.51kN/AN/A
Mr. Pierre Labbe C.A., C.P.A., CA, CPA, ICDChief Financial Officer534.87kN/A1965
Dr. Jeremy R. GraffChief Scientific OfficerN/AN/AN/A
Ms. Joy Bessenger B.A.Sr. VP of Investor Relations & Corp. StrategyN/AN/AN/A
Ms. Annie Tanguay B.Sc.Sr. VP of Quality & ComplianceN/AN/AN/A
Delphine DavanSr. Director of CommunicationsN/AN/AN/A
Ms. Linda Barabe M.B.A.VP of HRN/AN/AN/A
Dr. Marianne StanfordVP of R&DN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

IMV Inc., a biopharmaceutical company, focuses on the development of cancer immunotherapies and vaccines against infectious diseases using its DPX delivery technology platform. The company's lead drug candidate includes maveropepimut-S (DPX-Survivac), a T cell therapy, which is in three Phase II clinical trials across 6 different cancer indications with and without Merck's Keytruda; and Phase II clinical trials for the treatment of ovarian cancer, and recurrent and refractory diffuse large B cell lymphoma. It is also developing DPX-COVID-19, a second-generation vaccine against severe acute respiratory syndrome coronavirus 2; and DPX-RSV, a vaccine candidate, which has completed Phase I clinical trials for the treatment of respiratory syncytial virus strain A, as well as DPX-SurMAGE for the treatment of bladder cancer and DPX-BRAF to treat melanoma patients. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

Corporate Governance

IMV Inc.’s ISS Governance QualityScore as of September 26, 2021 is 6. The pillar scores are Audit: 4; Board: 8; Shareholder Rights: 6; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.